Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Bullish on Insmed (INSM); Raises PT to $22
May 22, 2013 10:44 AM EDTLeerink Swann today maintained an Outperform rating on Insmed (NASDAQ: INSM) and raised its price target to $22.00 (from $13.00). Increased bullishness follows additional data on Arikace in cystic fibrosis (CF) and non-tuberculous mycobacteria (NFM).
"Since our initiation in early March, INSM has... More
